Results 251 to 260 of about 149,070 (296)

Decitabine-cedazuridine in patients with MDS and TP53 mutations. [PDF]

Blood Adv
Urrutia S, Sasaki K, Bataller A, Kantarjian H, Montalban-Bravo G, McCloskey J, Griffiths EA, Yee K, Zeidan A, Savona M, Oganesian A, Sano Y, Keer HN, Garcia-Manero G.   +13 more
europepmc   +1 more source

Impact of Surgical Approach on Survival and Recurrence in Borderline and Malignant Phyllodes Tumours: A Systematic Review and Meta‐Analysis

ANZ Journal of Surgery, EarlyView.
ABSTRACT Background Phyllodes tumours of the breast exhibit a spectrum of biologic behaviour, with a predisposition to recur locally and metastasize distantly in their malignant form. There are limited data regarding the optimal surgical approach. Objectives Our systematic review and meta‐analysis aimed to determine the impact of breast conserving ...
Christopher G. Harris, Gillian Heller, Farhad Azimi, Belinda Chan, Susannah Graham, Cindy Mak, Sanjay Warrier   +6 more
wiley   +1 more source

TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab. [PDF]

Int J Cancer
Fountzilas C, Rosario S, Witkiewicz AK, Withers HG, Bajor DL, Mukherjee S, Saltzman J, Maguire O, Minderman H, Chatley S, Tarquini ML, Whitworth A, Jurcevic J, Hsiao HH, Knudsen ES, Muhitch JB, Abrams SI, Kalinski P, Segal BH, Bakin A, Yuan G, Wang C, Attwood K, Iyer R, Boland PM.   +24 more
europepmc   +1 more source

Optical genome mapping detects cryptic high‐risk and targetable abnormalities in adult AML

British Journal of Haematology, EarlyView.
Summary Acute myeloid leukaemia (AML) risk stratification relies on cytogenetic and molecular abnormalities defined by European LeukemiaNet (ELN) 2022. Conventional cytogenetic techniques, including chromosomal banding analysis (CBA) and fluorescence in situ hybridization, have limited resolution and may miss cryptic events. Optical genome mapping (OGM)
Audrey Bidet, Elodie Laharanne, Manon Dos Santos, Anne‐Charlotte De Grande, Thibaut Leguay, Arnaud Pigneux, Eric Frison, Sandrine Achard, Stéphanie Dupont‐Moufakkir, Emilie Klein, Pierre‐Yves Dumas   +10 more
wiley   +1 more source

TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma. [PDF]

Ann Hematol
Liu S, Zhou S, Zhang W, Wang J, Wang L, Li C, Chen Y, Qi W, Yang P, Jing H.   +9 more
europepmc   +1 more source

MOLECULAR ANALYSIS OF THE TP53 R248Q MUTATION: IMPACT ON P53–APR-246 INTERACTION IN AML

LMF Bertoline, K Lima, MFL Carvalho, JA Machado-Neto   +3 more
openalex   +1 more source

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

British Journal of Haematology, EarlyView.
Summary Bridging therapy (BT) prior to brexucabtagene autoleucel (brexu‐cel) in mantle cell lymphoma (MCL) is supported by limited evidence. Here, we report BT modality and outcome in 176 patients at 15 centres in the United Kingdom. BT was delivered to 90% (158/176), the majority receiving standard chemotherapy +/− radiotherapy (53%) (SD chemo +/− RT)
Maeve A. O'Reilly, William Wilson, Bernard Maybury, Andrea Kuhnl, Claire Roddie, Ben Uttenthal, Rod Johnson, Rajesh Alajangi, Thomas Creasey, Ahmed Abdulgawad, Carlos Gonzalez Arias, Sunil Iyengar, Graeme Ferguson, Katerina Panopoulou, Alison Delaney, Angharad Pryce, Lourdes Rubio, Ceri Jones, Jonathan Lambert, Shweta Gupta, Amrith Mathew, Shenbagaram Kasivisvanathan, Olateni Awofisayo, Shreyas Hanmantgad, Graham P. Collins, Caroline Besley, Frances Seymour, Robin Sanderson, Sridhar Chaganti   +28 more
wiley   +1 more source

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma. [PDF]

Signal Transduct Target Ther
Mao Z, Peng J, Cao Y, Wang N, Wang J, Yang Y, Xu J, Meng F, Chen L, Mao X, Guo J, Zhou X, Zhang Y, Wei J.   +13 more
europepmc   +1 more source

Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes

British Journal of Haematology, EarlyView.
Multivariable‐adjusted associations between family history of haematological malignancy (FHHM) and survival outcomes by non‐Hodgkin lymphoma subtype [OS (A), EFS (B), LSS (C) and failure to achieve EFS at 24 months (D)]. Subtype‐specific analyses showed that FHHM was associated with significantly inferior EFS in MCL and inferior LSS in FL.
George A. Cholack, Raphael Mwangi, Prokop Vodička, Thomas M. Habermann, Verena Hinder, Dennis P. Robinson, Andrew L. Feldman, Thomas E. Witzig, Jose C. Villasboas, Stephen M. Ansell, Brian K. Link, Yucai Wang, Carrie A. Thompson, Susan L. Slager, Matthew Maurer, Anne J. Novak, James R. Cerhan   +16 more
wiley   +1 more source